EUCTR2017-003268-11-IT进行中（未招募）1 期
Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC in patients with somatostatin receptor positive tumors (neuroendocrine tumors) - NA
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histopathological diagnosis of sst2 positive neuroendocrine tumor metastatic or inoperable
- •Significant capitation of the tumor tissue using diagnostic imaging with OctreoScan or PET with 68Ga-octreotide
- •PET/TC with 18F-FDG
- •Patients should not have received additional treatments (for example chemotherapy or radiotherapy) from one month before to two months after completing the treatment with 90Y-DOTATOC
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •verified medullary invasion
研究者
相似试验
进行中（未招募）
1 期
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMASRelapsed or refractory DLBCL (DIFFUSE LARGE B CELL LYMPHOMAS) or MCL (MANTLE CELL LYMPHOMAS)MedDRA version: 17.0Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 17.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-003418-10-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI IRST - IRCCS35
进行中（未招募）
不适用
Peptide Receptor Radionuclide Therapy (PRRT) in advanced gastro-entero-pancreatic Neuroendocrine TumorsAdvanced gastro-entero-pancreatic Neuroendocrine Tumors, FDG-PET negative patientsMedDRA version: 16.0Level: HLGTClassification code 10014713Term: Endocrine neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003165-34-ITIRCCS-IRST of Meldola
进行中（未招募）
1 期
uclear Medicine therapy using synthetic somatostatin analogues that are radiolabelled with high-energy beta(-) emitting isotopes, for the treatment of tumors overexpressing somatostatin specific receptors (on the surface of the cell membrane) enable to bind and internalize the radiolabelled analogues mentioned aboveEUCTR2016-005129-35-ITAZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA250
终止
1 期
Peptide Receptor Radionuclide Therapy administered to Participants withMeningioma with 67Cu-SARTATE™Cancer - BrainCancer - Head and neckCancer - Other cancer typesMeningiomaACTRN12618000309280Clarity Pharmaceuticals Ltd.5
招募中
不适用
Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors.well-differentiated advanced gastroenteropancreatic neuro-endocrine tumors.NL-OMON21221Erasmus MC, Rotterdam, the Netherland24